Skip to Main Content

Author Details

Chiara Corti
University of Milano
2017
56
18
PMIDPaper TitleJournal TitlePublished Year
37983586Cardiotoxicity of Agents Used in Patients With Breast Cancer.JCO Oncol Pract2024
37715957Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.Oncologist2024
37548439Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.Oncologist2024
36630822High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study.Lung Cancer2023
37703594Artificial intelligence as an adjunct tool for breast oncologists - are we there yet?ESMO Open2023
37890353Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.Eur J Cancer2023
37835473MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.Cancers (Basel)2023
37644992Broadening the scope of artificial intelligence in oncology.Lancet Reg Health Am2023
37639757Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.Cancer Treat Rev2023
37146385Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?Cancer Treat Rev2023
37467660Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.ESMO Open2023
36971965HER2-Low Breast Cancer: a New Subtype?Curr Treat Options Oncol2023
37232842Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?Curr Oncol2023
37069173Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.NPJ Breast Cancer2023
37473517Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials.Cancer Treat Rev2023
36996620Future potential targets of antibody-drug conjugates in breast cancer.Breast2023
36743524Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives.Ther Adv Med Oncol2023
36900178Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution.Cancers (Basel)2023
36527795Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care.Cancer Treat Rev2023
34718117Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Ann Oncol2022
35609495Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias.Cancer Treat Rev2022
35468539Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.Cancer Treat Rev2022
35372498HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.Front Mol Biosci2022
35696887Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?Eur J Cancer2022
35820244Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.Eur J Cancer2022
35970033Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.Eur J Cancer2022
36140761Breast Cancer Genetics: Diagnostics and Treatment.Genes (Basel)2022
36098328Exploring biases in predictive modelling across diverse populations.Lancet Healthy Longev2022
36096156Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.Lancet Oncol2022
34953200Targeting brain metastases in breast cancer.Cancer Treat Rev2022
35311430CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.Expert Opin Investig Drugs2022
35181659Immunotherapy for early triple negative breast cancer: research agenda for the next decade.NPJ Breast Cancer2022
35306318SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis.Eur J Cancer2022
35305211Bystander effect of antibody-drug conjugates: fact or fiction?Curr Oncol Rep2022
34767258Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.CA Cancer J Clin2022
34823982Therapeutic vaccines for breast cancer: Has the time finally come?Eur J Cancer2022
33450404Commentary: SARS-CoV-2 vaccines and cancer patients.Ann Oncol2021
33878560Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis.Cancer Treat Rev2021
33676293Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.ESMO Open2021
34967317Systemic Treatment of Ductal Carcinoma In Situ of the Breast.Chirurgia (Bucur)2021
34500046Therapeutic cancer vaccines revamping: technology advancements and pitfalls.Ann Oncol2021
34763593Novel immune targets for the treatment of triple-negative breast cancer.Expert Opin Ther Targets2021
34577584Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies.Pharmaceuticals (Basel)2021
34455288Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials.ESMO Open2021
34830983Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials.Cancers (Basel)2021
34186441First line treatment of BRAF mutated advanced melanoma: Does one size fit all?Cancer Treat Rev2021
34207890Antibody-Drug Conjugates for the Treatment of Breast Cancer.Cancers (Basel)2021
34029683Managing side effects of immune checkpoint inhibitors in breast cancer.Crit Rev Oncol Hematol2021
32852309Adjuvant treatment of early male breast cancer.Curr Opin Oncol2020
32098071PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.Int J Mol Sci2020
  • 1 - 50 of 56

Recommended Authors

Amrita Basu
University of California San Francisco
Career Start Year 2018
Number of shared co-authors 1
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 4
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 1
Theodora Goulioti
Career Start Year 2009
Number of shared co-authors 1
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 1
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 0
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 1
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 1
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 0
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 0
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 2
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 3
Lissandra Dal Lago
Institut Jules Bordet
Career Start Year 2002
Number of shared co-authors 1
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 3
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 3
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 4
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 0
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 2
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 2
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 3
Carolien P Schr??der
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 0
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 1
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 1
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 1
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 3
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 1
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Career Start Year 1987
Number of shared co-authors 4
Eric P Winer
Dana-Farber Cancer Institute
Career Start Year 1985
Number of shared co-authors 5
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 0

Collaborators

Giuseppe Curigliano
University of Milan
Co-authored papers 40
Carmen Criscitiello
University of Milano
Co-authored papers 22
Nicola Fusco
IEO European Institute of Oncology IRCCS
Co-authored papers 10
Sara M Tolaney
Dana-Farber Cancer Institute
Co-authored papers 6
Leo Anthony Celi
Harvard T.H. Chan School of Public Health, MIT
Co-authored papers 4
Edward Christopher Dee
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Lisa A Carey
Co-authored papers 2
Giuseppe Giaccone
Meyer Cancer Center
Co-authored papers 2
Silvano Bosari
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Co-authored papers 2
Massimo Cristofanilli
Weill Cornell School of Medicine
Co-authored papers 2
Alberto Zambelli
IRCCS Humanitas Research Hospital
Co-authored papers 1
Revathi Ravella
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
Marisa Cobanaj
Polytechnic University of Milan
Co-authored papers 1
Puneeth Iyengar
UT Southwestern Medical Center, Center for Human Nutrition
Co-authored papers 1
Nancy U Lin
Co-authored papers 1
Giorgio P Biondetti
Co-authored papers 1
Andra Dombrovschi
Co-authored papers 1
Sara Marcu
Co-authored papers 1
Nishwant Swami
University of Massachusetts Medical School, Harvard TH Chan School of Public Health
Co-authored papers 1
Federica Marian
Co-authored papers 1
Francesco DiMeco
Co-authored papers 1
Aditya Bardia
Massachusetts General Hospital Cancer Center
Co-authored papers 1
Felipe Batalini
Mayo Clinic Arizona
Co-authored papers 1
Marisa Cobanaj
National Center for Radiation Research in Oncology (HZDR)
Co-authored papers 1
Maxwell R Lloyd
Beth Israel Deaconess Medical Center
Co-authored papers 1
Mary L Disis
University of Washington Medicine Cancer Vaccine Institute, University of Washington
Co-authored papers 1
Release 1.2